Among all the growth hormone-related peptides available today, tesamorelin occupies a unique position: it's the only GHRH analog with full FDA approval, backed by gold-standard clinical trial data showing significant visceral fat reduction. For patients who want meaningful GH benefits — particularly around abdominal fat — without the risks of injecting synthetic HGH, tesamorelin represents the most evidence-backed option available.
What Is Tesamorelin?
Tesamorelin (brand name: Egrifta) is a synthetic analog of growth hormone-releasing hormone (GHRH) — the natural signal from the hypothalamus that triggers GH release from the pituitary. Like CJC-1295, it works by stimulating your own pituitary to release GH, preserving the natural feedback loop that keeps GH levels in check.
The FDA approved tesamorelin in 2010 for the treatment of excess abdominal fat (lipodystrophy) in adults with HIV on antiretroviral therapy — a condition that causes severe visceral fat accumulation. Its ability to reduce visceral fat without the broad risks of exogenous HGH has also made it attractive in anti-aging and metabolic medicine.
Tesamorelin is the only GH-stimulating peptide with FDA approval. While this approval is specifically for HIV-associated lipodystrophy, the clinical data on visceral fat reduction, liver fat, and GH axis restoration is directly applicable to other contexts under physician supervision.
Visceral Fat: Why It Matters
Not all fat is created equal. Visceral fat — the deep abdominal fat that surrounds your organs — is metabolically active in harmful ways. It secretes inflammatory cytokines, contributes to insulin resistance, and is a major driver of cardiovascular and metabolic disease risk. Diet and exercise can reduce subcutaneous fat but often struggle to move visceral fat.
In the pivotal tesamorelin trials, patients reduced visceral adipose tissue by an average of 15–18% over 26 weeks. This is a clinically meaningful reduction with real health implications beyond appearance.
NAFLD and Liver Fat Data
Emerging research has also investigated tesamorelin's effects on liver fat in non-alcoholic fatty liver disease (NAFLD). A randomized trial showed that tesamorelin reduced liver fat content by approximately 32% compared to placebo — a remarkable finding for patients with early liver disease who have few pharmaceutical options.
Why Prefer Tesamorelin Over Raw HGH?
| Factor | Tesamorelin | Synthetic HGH |
|---|---|---|
| Mechanism | Stimulates pituitary (physiological) | Bypasses pituitary (pharmacological) |
| Feedback Loop | Preserved — self-regulating | Suppressed |
| Acromegaly Risk | Very low (pituitary self-limits) | Present with excess dosing |
| FDA Status | FDA-approved (GHRH analog) | FDA-approved for deficiency only |
| Visceral Fat Data | Strong RCT evidence | Moderate evidence |
| Cost | Lower (compounded available) | Very high |
Anti-Aging and Longevity Applications
Beyond its FDA-approved indication, tesamorelin is increasingly used by longevity-focused physicians for:
- Restoration of GH axis function that declines with age
- Reduction of visceral fat in metabolically unhealthy patients without HIV
- Improvements in lean body mass and body composition
- Cognitive benefits (GH supports brain health and mood)
- Improved lipid profile (reduced triglycerides is a consistent finding)
Dosing Protocol
| Parameter | Details |
|---|---|
| Standard Dose | 2 mg/day (FDA-approved dose) |
| Anti-Aging Dose | 1–2 mg/day (physician-adjusted) |
| Administration | Subcutaneous injection, abdomen |
| Timing | Before bed (aligns with natural GH pulse) |
| Cycle | 6+ months for maximal visceral fat reduction |
| Monitoring | IGF-1, fasting glucose, lipid panel at 3 months |
Frequently Asked Questions
Can I use tesamorelin if I don't have HIV?
Yes — tesamorelin can be prescribed off-label by a licensed physician for conditions like visceral obesity, GH deficiency, or metabolic syndrome. The clinical data is applicable regardless of HIV status.
Is tesamorelin the same as CJC-1295?
Both are GHRH analogs, but tesamorelin is a closer structural analog of native GHRH and has FDA-approved clinical data. CJC-1295 is more commonly available through compounding pharmacies. Your provider can help determine which is more appropriate.
Will I need to stay on it indefinitely for the fat loss to persist?
Studies show that visceral fat tends to return after stopping tesamorelin, suggesting ongoing treatment is needed to maintain results — similar to other weight management interventions.